BEVERLY TCHANG: Open Payments
NPI 1194067587 · NEW YORK, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$70,720 in 57 payments from 9 companies in 2025. Trend: 2023 $12,390 · 2024 $26,067 · 2025 $70,720
Consulting: $58,158Travel & lodging: $10,672Food & beverage: $1,890
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 16 | $25,999 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 24 | $20,226 |
| Eli Lilly and Company | 4 | $13,979 |
| Amgen Inc. | 1 | $4,470 |
| F. Hoffmann-La Roche AG | 1 | $2,700 |
| Madrigal Pharmaceuticals | 4 | $2,064 |
| PFIZER INC. | 1 | $1,200 |
| Lilly USA, LLC | 5 | $67 |
| Genentech, Inc. | 1 | $14 |
Products named: Ozempic, ZEPBOUND, REZDIFFRA, Wegovy, MOUNJARO.
Industry payments across NY — which companies pay providers there.
